The research aims to explore TRIM21's role in regulating STAT1 and its impact on metabolic dysfunction associated with steatohepatitis.
Analysis of TRIM21's effects on STAT1 regulation
Examination of ubiquitination processes in metabolic dysfunction
Evaluation of TRIM21's impact on hepatic steatosis
TRIM21 suppresses STAT1 through ubiquitination
TRIM21's role as a negative regulator of metabolic dysfunction is confirmed
Potential therapeutic implications for targeting TRIM21 in steatohepatitis are highlighted
Abstract
The ubiquitination of STAT1 in MASH is regulated by TRIM21 which is a key suppressor of MASH. TRIM21 acts as a negative regulator in hepatic steatosis and offers potential therapeutic opportunities for MASH.